Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary C Brown

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Current Opinion in Ophthalmology|April 13, 2011
Changes in the practice of vitreoretinal disease. EditorialGary C Brown
Current Opinion in Ophthalmology|May 1, 2004
One eye versus two: a value-based approachGary C Brown
Current Opinion in Ophthalmology|June 24, 2006
56,000 Ways? No way!Gary C Brown
Current Opinion in Ophthalmology|April 11, 2012
Advances in quality-of-life and the financial independence of patientsGary C Brown
Current Opinion in Ophthalmology|May 5, 2005
Value-based medicine: the new paradigmGary C Brown
Current Opinion in Ophthalmology|April 4, 2013
We are producers of patient value and financial valueGary C Brown
Current Opinion in Ophthalmology|June 5, 2003
Update on treatment of retinal arterial occlusionsShimon Rumelt, Gary C Brown
Current Opinion in Ophthalmology|June 5, 2003
Update on photodynamic therapyJennifer Landy, Gary C Brown
Current Opinion in Ophthalmology|May 9, 2009
Stem-cell therapy in retinal diseasePaul S Baker, Gary C Brown
Ophthalmology|September 24, 2019
Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424)Gary C Brown, Melissa M Brown
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Current Opinion in Ophthalmology|April 13, 2011
Changes in the practice of vitreoretinal disease. EditorialGary C Brown
Current Opinion in Ophthalmology|May 1, 2004
One eye versus two: a value-based approachGary C Brown
Current Opinion in Ophthalmology|June 24, 2006
56,000 Ways? No way!Gary C Brown
Current Opinion in Ophthalmology|April 11, 2012
Advances in quality-of-life and the financial independence of patientsGary C Brown
Current Opinion in Ophthalmology|May 5, 2005
Value-based medicine: the new paradigmGary C Brown
Current Opinion in Ophthalmology|April 4, 2013
We are producers of patient value and financial valueGary C Brown
Current Opinion in Ophthalmology|June 5, 2003
Update on treatment of retinal arterial occlusionsShimon Rumelt, Gary C Brown
Current Opinion in Ophthalmology|June 5, 2003
Update on photodynamic therapyJennifer Landy, Gary C Brown
Current Opinion in Ophthalmology|May 9, 2009
Stem-cell therapy in retinal diseasePaul S Baker, Gary C Brown
Ophthalmology|September 24, 2019
Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424)Gary C Brown, Melissa M Brown
Pageof 12